IT
Seleziona lingua

Language

Bracco Research & Innovation

 



For years the Bracco Group has been investing substantial resources in research, pre-clinical and clinical development of Imaging Agents for in vivo imaging. IA are used with special equipment to provide physicians with detailed information for diagnoses and to monitor minimally invasive operating procedures. Technological advances in equipment, combined with IA, permit a very high level of diagnostic accuracy and procedure monitoring for most pathologies.

Iopamidol, the first molecule discovered and developed by Bracco in 1981, was followed by other IA created,developed and marketed by Bracco for X-ray, Magnetic Resonance, Ultrasound and Nuclear Medicine. In the last few years, the Group has acquired competences and research skills in imaging-related sectors such as automatic IA delivery systems – at the Acist laboratories in Minneapolis, USA – and medical software for quantitative analysis of images. Its research work has a specific goal: to improve and facilitate diagnostic accuracy and treatment procedures to optimize medical services for patients.

Bracco WorldWide

Bracco WorldWide

The Bracco Group, through its subsidiary Bracco Imaging operates throughout the world both directly or indirectly.

Bracco WorldWide

Read more

Diagnostic Imaging

Diagnostic Imaging

Bracco Imaging is an international leader in diagnostic imaging.

Diagnostic Imaging

Read more

Bracco Group's History

Our History

The Bracco Group exists since 1927, when Elio Bracco founded the Italian E. Merck company branch.

Bracco Group's History

Read more